Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects chronically infected with HCV genotype 1
Non-responder to prior therapy with peginterferon alfa and ribavirin
HCV RNA viral load of 100,00 IU/mL
Results of a liver biopsy ≤ 24 months prior to randomization consistent with chronic HCV infection; for compensated cirrhotics can be any time prior to randomization (compensated cirrhotics biopsy enrollment will be capped at 25% of randomized study population)
Ultrasound, CT scan or MRI results 12 months prior to randomization that do not demonstrate hepatocellular carcinoma
Body Mass Index (BMI) of 18 to 35 kg/m2
You may not be if
Positive for Hepatitis B infection (HBsAg) or HIV-1/HIV-2 antibody at screening
Evidence of medical condition associated with chronic liver disease other than HCV
Evidence of decompensated cirrhosis based on radiologic criteria or biopsy
